Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 neoadjuvant visugromab plus nivolumab versus nivolumab alone in muscle-invasive bladder cancer
2022-002816-22Phase 2Active
- Sponsor
- CatalYm
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of visugromab and nivolumab in muscle-invasive bladder cancer (MIBC) and bladder cancer (2 arms), sponsored by CatalYm. Primary endpoint: Pathologic complete response rate. Started Nov 2022; status: active.
02
Drugs
visugromabnivolumab
03
Conditions
muscle-invasive bladder cancer (MIBC)bladder cancer
Beyond the preview
Go deeper on 2022-002816-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002816-22.